title: Safety and Biodistribution Evaluation in Cynomolgus Macaques of rAAV2tYF-PR1.7-hCNGB3, a Recombinant AAV Vector for Treatment of Achromatopsia.
abstract: Applied Genetic Technologies Corporation (AGTC) is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated viral (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity, and absence of color discrimination. We report here results of a study evaluating the safety and biodistribution of rAAV2tYF-PR1.7-hCNGB3 in cynomolgus macaques. Three groups of animals (n = 2 males and 2 females per group) received a subretinal injection in one eye of 300 μl containing either vehicle or rAAV2tYF-PR1.7-hCNGB3 at one of two concentrations (4 × 10(11) or 4 × 10(12) vector genomes/ml) and were evaluated over a 3-month period before being euthanized. Administration of rAAV2tYF-PR1.7-hCNGB3 was associated with a dose-related anterior and posterior segment inflammatory response that was greater than that observed in eyes injected with the vehicle control. Most manifestations of inflammation improved over time except that vitreous cells persisted in vector-treated eyes until the end of the study. One animal in the lower vector dose group was euthanized on study day 5, based on a clinical diagnosis of endophthalmitis. There were no test article-related effects on intraocular pressure, visual evoked potential responses, hematology or clinical chemistry parameters, or gross necropsy observations. Histopathological examination demonstrated minimal mononuclear infiltrates in all vector-injected eyes. Serum anti-AAV antibodies developed in all vector-injected animals. No animals developed antibodies to CNGB3. Biodistribution studies demonstrated high levels of vector DNA in the injected eye but minimal or no vector DNA in any other tissue. These results support the use of rAAV2tYF-PR1.7-hCNGB3 in clinical studies in patients with achromatopsia caused by CNGB3 mutations.
authors.affiliation: 1 Applied Genetic Technologies Corporation (AGTC) , Alachua, FL.
authors.forename: Guo-jie
authors.initials: GJ
authors.lastname: Ye
authors.affiliation: 2 Covance Laboratories , Madison, WI.
authors.forename: Ewa
authors.initials: E
authors.lastname: Budzynski
authors.affiliation: 2 Covance Laboratories , Madison, WI.
authors.forename: Peter
authors.initials: P
authors.lastname: Sonnentag
authors.affiliation: 3 OSOD (Ocular Services On Demand) , Madison, WI.
authors.forename: T Michael
authors.initials: TM
authors.lastname: Nork
authors.affiliation: 3 OSOD (Ocular Services On Demand) , Madison, WI.
authors.forename: Paul E
authors.initials: PE
authors.lastname: Miller
authors.affiliation: 2 Covance Laboratories , Madison, WI.
authors.forename: Alok K
authors.initials: AK
authors.lastname: Sharma
authors.affiliation: 3 OSOD (Ocular Services On Demand) , Madison, WI.
authors.forename: James N
authors.initials: JN
authors.lastname: Ver Hoeve
authors.affiliation: 4 Laboratory Corporation of America Holdings , Seattle, WA.
authors.forename: Leia M
authors.initials: LM
authors.lastname: Smith
authors.affiliation: 2 Covance Laboratories , Madison, WI.
authors.forename: Tara
authors.initials: T
authors.lastname: Arndt
authors.affiliation: 5 University of Pennsylvania , Philadelphia, PA.
authors.forename: Roberto
authors.initials: R
authors.lastname: Calcedo
authors.affiliation: 1 Applied Genetic Technologies Corporation (AGTC) , Alachua, FL.
authors.forename: Chantelle
authors.initials: C
authors.lastname: Gaskin
authors.affiliation: 1 Applied Genetic Technologies Corporation (AGTC) , Alachua, FL.
authors.forename: Paulette M
authors.initials: PM
authors.lastname: Robinson
authors.affiliation: 1 Applied Genetic Technologies Corporation (AGTC) , Alachua, FL.
authors.forename: David R
authors.initials: DR
authors.lastname: Knop
authors.affiliation: 6 University of Florida , Gainesville, FL.
authors.forename: William W
authors.initials: WW
authors.lastname: Hauswirth
authors.affiliation: 1 Applied Genetic Technologies Corporation (AGTC) , Alachua, FL.
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Chulay
mesh_terms: D000818:Animals; D003117:Color Vision Defects / Q000628:therapy*; D054815:Cyclic Nucleotide-Gated Cation Channels / Q000235:genetics* / Q000378:metabolism; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000009:adverse effects*; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D056965:Injections, Intraocular; D008252:Macaca fascicularis; D008297:Male
chemical_list: C415904:CNGB3 protein, human; D054815:Cyclic Nucleotide-Gated Cation Channels; D004274:DNA, Recombinant